Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795323 · ClinicalTrials.gov registry record · Phase 2
Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD
A Phase 2 study of Pulmonary Disease, Chronic Obstructive, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 2
- Study locations
NCT04795323 is a Phase 2 study of Pulmonary Disease, Chronic Obstructive that has completed, run by Boehringer Ingelheim. The registered enrollment target is 5 participants, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04795323, a Phase 2 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with Technology-Assisted Respiratory Adherence prototype 3. The study's secondary aim is to assess whether there is an associated maintenance or increase in activities of daily living to support a positive benefit of Technology-Assisted Respiratory Adherence prototype 3 on breathlessness and whether there is an improvement in the physical activity experience of the patient.
Conditions Studied
Interventions
- DEVICE TARA v3.1, only non-pharmacological self-management support
- DEVICE TARA v3.2, both non-pharmacological and pharmacological self-management support
Study Locations (2)
North Carolina
- Clinical Research of Gastonia - Gastonia
South Carolina
- Lowcountry Lung and Critical Care - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-04-08 |
| Est. Completion | 2022-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04795323
The ClinicalTrials.gov registry entry for NCT04795323 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,044-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (100% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 2 interventions - of which TARA v3.1, only non-pharmacological self-management support is the first listed.
NCT04795323 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, South Carolina.
Frequently Asked Questions
What is clinical trial NCT04795323 about?
NCT04795323 is a clinical study titled "Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPD". The study's primary aim is to assess whether there is a clinically significant reduction in breathlessness in symptomatic individuals with chronic obstructive respiratory disease (IwCOPD) following engagement with Technology-Assisted Respiratory Adherence prototype 3. The study's secondary aim is t...
What is the current status of trial NCT04795323?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-04-08. Estimated completion is 2022-03-12.
What conditions does trial NCT04795323 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT04795323?
The interventions under investigation include: TARA v3.1, only non-pharmacological self-management support (DEVICE), TARA v3.2, both non-pharmacological and pharmacological self-management support (DEVICE).
Who is sponsoring clinical trial NCT04795323?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04795323 being conducted?
This trial has 2 study locations across North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
COMPLETED · Phase 2
-
Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
COMPLETED · Phase 2
-
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.
COMPLETED · Phase 2
-
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.